Welcome to our dedicated page for Regencell Bioscience Holdings SEC filings (Ticker: RGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regencell Bioscience Holdings Limited (NASDAQ: RGC) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Form 6‑K current reports and other documents filed as a foreign private issuer. Regencell is an early-stage bioscience company that focuses on Traditional Chinese Medicine (TCM) formulae for ADHD, ASD and infectious diseases affecting the immune system, and its filings offer insight into how this strategy is reflected in its governance, financial reporting and material events.
Through its Form 6‑K submissions, Regencell furnishes information such as unaudited condensed consolidated interim financial statements, management financial results for specific periods, and board and committee changes. For example, the company has reported the appointment and resignation of independent directors, including details on committee roles and confirmation that certain resignations were not due to disagreements over operations, policies or practices. These filings help investors understand the composition of the audit, compensation and nominating and corporate governance committees that oversee the company’s activities.
Regencell’s filings also reference Schedule 13D reports filed by its Chairman and Chief Executive Officer, documenting open-market purchases of ordinary shares and resulting ownership levels. While the Schedule 13D forms themselves are filed separately, company press releases and 6‑K reports highlight these insider transactions, which some investors track to gauge management’s alignment with shareholders.
On Stock Titan, each new Regencell filing is captured in near real time from the SEC’s EDGAR system. AI-powered summaries are provided to explain the key points of lengthy documents in plain language, helping readers quickly identify items such as changes in director appointments, committee assignments, and furnished financial data. Users can review historical 6‑K submissions and related exhibits to follow Regencell’s evolution as an early-stage TCM-focused bioscience company, while AI-generated overviews reduce the time needed to interpret complex regulatory text.
Regencell Bioscience Holdings Limited has extended the lock-up period for directors and employees who previously received stock options. All such employees agreed that 100% of their shares and vested options will remain locked up for an additional 12 months, until April 20, 2027. Directors agreed that between 82% and 92% of their shares and vested options will also remain subject to this extended lock-up over the same period. A standard form of this fifth lock-up extension is included as an exhibit and is governed by New York law.
Regencell Bioscience Holdings (RGC) filed its annual Form 20‑F, outlining an early‑stage TCM bioscience business focused on ADHD and ASD with no approved products and continued losses. The company reported net losses of $3.58 million for fiscal 2025 and $4.36 million for 2024, reflecting ongoing R&D and administrative spend. As of June 30, 2025, 494,488,908 ordinary shares were outstanding.
On June 13, 2025, RGC executed a 38‑for‑1 forward stock split by capitalizing its share premium, issuing additional shares with no cash outflow and no change to authorized capital or par value. The auditor included a going concern explanatory paragraph, citing recurring losses and funding needs. Management also disclosed material weaknesses in internal controls over financial reporting, including limited U.S. GAAP/SEC reporting expertise, absence of an internal audit function, and segregation‑of‑duties gaps. The filing highlights substantial execution, regulatory and commercialization risks, and notes recent extreme share‑price volatility unrelated to operating changes.
FAQ
What is the current stock price of Regencell Bioscience Holdings (RGC)?
What is the market cap of Regencell Bioscience Holdings (RGC)?
